Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Sana Biotechnology Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.35 (market cap $162.00B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 193.6× Sana Biotechnology Inc's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Sana Biotechnology Inc for 23 Days on average.
| IEMG | SANA | |
|---|---|---|
Market Cap | $162.00B | $836.71M |
Volume | 13,446,151 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $5.92 |
52-Week Low | $64.22 | $2.68 |
Typical Hold Time | 57 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.29, down 0.91% with bearish technical signals dominating. The ETF faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers and its appeal for long-term portfolio strategies despite higher volatility compared to developed market alternatives.
The outlook remains cautious given technical weakness, though emerging market exposure offers growth potential. Key risks include sector concentration in technology and emerging market volatility. Analyst comparisons favor IEMG for cost efficiency and performance, but investors should weigh higher drawdowns against return potential.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
